The findings provide usefulinsights for the development of SIRT3 inhibitors and mitochondrialtargeting agents and further support the notion that SIRT3 is a promisingdruggable target for DLBCL. This evidence concerns the gene SIRT3 and diffuse large B-cell lymphoma.